Currently Viewing:
Newsroom
Currently Reading
Study Shows That Volanesorsen Reduces Disease Burden in Patients With FCS
June 17, 2018 – Kelly Davio
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15, 2018 – Laura Joszt
With Payer Coverage, Food Is Medicine Movement Takes Flight
June 15, 2018 – Mary Caffrey
The Common Factor in Models Trying to Predict COPD: Smoking
June 15, 2018 – Allison Inserro
5 Updates on Maternal Health in the United States
June 15, 2018 – Surabhi Dangi-Garimella, PhD
FDA Approves First Generic Version of Suboxone for Opioid Dependence
June 15, 2018 – Jaime Rosenberg
Experts Suggest Interventions for High-Need Patients
June 15, 2018 – Alison Rodriguez
What We're Reading: Government Doesn't Owe Insurers ACA Money; Hep A Outbreak; Risky Teen Behaviors
June 15, 2018 – AJMC Staff
This Week in Managed Care: June 15, 2018
June 15, 2018

Orphan Drug Market to Continue Steady Growth; Sales to Double Between 2016 and 2022

Laura Joszt
The orphan drug market continues its steady and inexorable growth even with increased scrutiny on the high prices of these lifesaving treatments.
The orphan drug market continues its steady and inexorable growth even with increased scrutiny on the high prices of these lifesaving treatments.

According to EvaluatePharma’s Orphan Drug Report 2017, insurers will continue to cover orphan drugs, which will drive continued growth of the market. Sales of orphan drugs are expected to double between 2016 and 2022. By 2022, worldwide orphan drug sales are expected to total $209 billion and orphan drugs are set to be 21.4% of brand-name prescription drugs.

“The image of the plucky small biotech striving to develop treatments for the rare diseases largely ignored by big pharma is long gone,” Lisa Urquhart, EP Vantage editor and report contributor, said in a statement. “Instead, this year we again find big pharma dominating the sector.”

The report estimates that the average cost per patient in 2016 for an orphan drug was $140,443 compared with $27,756 for a non-orphan drug. There is a clear correlation between revenue per patient and the number of patients treated. Soliris, which is approved to treat patients with paroxysmal nocturnal hemoglobinuria, is one of the most expensive drugs in the world and was the highest revenue orphan drug in 2016, but it treats a very small patient population.

EvaluatePharma predicts that Revlimid, approved to treat myelodysplastic syndrome, orphan indications of Non-Hodgkin’s lymphoma, and multiple myeloma, will be the top-selling orphan drug in the world in 2022. Celgene, which makes Revlimid, will have the most orphan drug sales worldwide.

However, Urquhart and report co-author Andreas Hadjivasiliou, an analyst at EvaluatePharma, warn that payers and politicians are taking note of the industry more than ever before.

“As such, if the orphan drug industry is to continue to thrive, it must continue to generate innovations that justify the huge cost of these life-transforming treatments,” they wrote.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!